Literature DB >> 29887327

Myeloperoxidase-ANCA-positive granulomatosis with polyangiitis is a distinct subset of ANCA-associated vasculitis: A retrospective analysis of 455 patients from a single center in China.

Dong-Yuan Chang1, Zhi-Ying Li1, Min Chen2, Ming-Hui Zhao1.   

Abstract

OBJECTIVE: Antineutrophil cytoplasmic antibody (ANCA) directed to proteinase 3 (PR3) used to be considered the serologic marker for granulomatosis with polyangiitis (GPA). However, patients with myeloperoxidase (MPO)-ANCA positive GPA have been increasingly reported. The aim of this study was to analyze the clinical and pathological characteristics and outcome of Chinese patients with MPO-ANCA positive GPA.
METHODS: The clinical and renal histology data, renal outcomes, response to treatment, relapse and mortality were compared between patients with MPO-ANCA positive GPA and MPO-ANCA positive microscopic polyangiitis (MPA) as well as proteinase 3 (PR3)-ANCA positive GPA.
RESULTS: 455 patients with ANCA-associated vasculitis (AAV) were recruited in this study. 276/455 patients were classified as MPO-ANCA positive MPA, 4/455 patients were classified as PR3-ANCA positive MPA, 124/455 were MPO-ANCA positive GPA and 51/455 were PR3-ANCA positive GPA. Compared with MPO-ANCA positive MPA patients, MPO-ANCA positive GPA patients had significantly higher level of BVAS and milder renal lesion at diagnosis. The probability of developing ESRD was significantly higher in patients with MPO-ANCA positive MPA than MPO-ANCA positive GPA. MPO-ANCA positive GPA patients were likely to have relapse than MPO-ANCA positive MPA patients. Compared with PR3-ANCA positive GPA patients, MPO-ANCA positive GPA patients had significantly higher proportion of female, less constitutional symptoms and milder renal lesion at diagnosis.
CONCLUSIONS: Patients with MPO-ANCA positive GPA should be regarded as a unique subset of AAV. This subset of AAV patients had relatively milder renal injury. Although ANCA specificities play an important role in differentiating AAV, taking the disease type together to classify AAV may be more rational.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ANCA; Granulomatosis with polyangiitis; Myeloperoxidase; Proteinase 3; Vasculitis

Mesh:

Substances:

Year:  2018        PMID: 29887327     DOI: 10.1016/j.semarthrit.2018.05.003

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  10 in total

1.  Predictors of poor prognosis in ANCA-associated vasculitis (AAV): a single-center prospective study of inpatients in China.

Authors:  Ronglin Gao; Zhenzhen Wu; Xianghuai Xu; Jincheng Pu; Shengnan Pan; Youwei Zhang; Shuqi Zhuang; Lufei Yang; Yuanyuan Liang; Jiamin Song; Jianping Tang; Xuan Wang
Journal:  Clin Exp Med       Date:  2022-10-16       Impact factor: 5.057

Review 2.  Antineutrophil cytoplasmic antibodies (ANCA) - their role in pathogenesis, diagnosis, and treatment monitoring of ANCA-associated vasculitis.

Authors:  Justyna FijoŁek; ElŻbieta Wiatr
Journal:  Cent Eur J Immunol       Date:  2020-07-09       Impact factor: 2.085

3.  Pulmonary involvement of ANCA-associated vasculitis in adult Chinese patients.

Authors:  Peining Zhou; Zhiying Li; Li Gao; Chengli Que; Haichao Li; Jing Ma; Guangfa Wang; Min Chen
Journal:  BMC Pulm Med       Date:  2022-01-12       Impact factor: 3.317

4.  Gene polymorphisms in ULK1 and PIK3CA are associated with the risk of microscopic polyangiitis in the Guangxi Zhuang Autonomous Region in China.

Authors:  Yan Zhu; Jinlan Rao; Jingsi Wei; Liu Liu; Shanshan Huang; Jingjing Lan; Chao Xue; Wei Li
Journal:  PeerJ       Date:  2021-11-09       Impact factor: 2.984

5.  Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry.

Authors:  Xavier Puéchal; Michele Iudici; Christian Pagnoux; Pascal Cohen; Mohamed Hamidou; Achille Aouba; François Lifermann; Marc Ruivard; Olivier Aumaître; Bernard Bonnotte; Francois Maurier; Thomas Le Gallou; Eric Hachulla; Alexandre Karras; Chahéra Khouatra; Noémie Jourde-Chiche; Jean-François Viallard; Claire Blanchard-Delaunay; Pascal Godmer; Alain Le Quellec; Thomas Quéméneur; Claire de Moreuil; Luc Mouthon; Benjamin Terrier; Loïc Guillevin
Journal:  RMD Open       Date:  2022-03

Review 6.  ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives.

Authors:  Keziah Austin; Shalini Janagan; Matthew Wells; Helena Crawshaw; Stephen McAdoo; Joanna C Robson
Journal:  J Inflamm Res       Date:  2022-04-21

Review 7.  Advances in the genomics of ANCA-associated vasculitis-a view from East Asia.

Authors:  Aya Kawasaki; Naoyuki Tsuchiya
Journal:  Genes Immun       Date:  2021-03-08       Impact factor: 2.676

Review 8.  Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide?

Authors:  Zachary S Wallace; John H Stone
Journal:  Front Immunol       Date:  2019-12-06       Impact factor: 7.561

9.  Outcome Predictors of Biopsy-Proven Myeloperoxidase-Anti-Neutrophil Cytoplasmic Antibody-Associated Glomerulonephritis.

Authors:  Yifei Ge; Guang Yang; Xiangbao Yu; Bin Sun; Bo Zhang; Yanggang Yuan; Ming Zeng; Ningning Wang; Huijuan Mao; Changying Xing
Journal:  Front Immunol       Date:  2021-02-04       Impact factor: 7.561

10.  Systemic immune-inflammation index predicts a reduced risk of end-stage renal disease in Chinese patients with myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated vasculitis: A retrospective observational study.

Authors:  Jin-Biao Chen; Rong Tang; Yong Zhong; Ya-Ou Zhou; Xiaoxia Zuo; Hui Luo; Li Huang; Wei Lin; Ting Wu; Yingqiang Yang; Ting Meng; Zhou Xiao; Xiang Ao; Xiangcheng Xiao; Qiaoling Zhou; Ping Xiao
Journal:  Exp Ther Med       Date:  2021-07-13       Impact factor: 2.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.